NASDAQ:GERN - Geron Stock Price, Forecast & News

Geron trades on the NASDAQ under the ticker symbol "GERN."

Geron Co. (NASDAQ:GERN) released its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.06. The biopharmaceutical company earned $0.13 million during the quarter, compared to analysts' expectations of $0.10 million. Geron had a negative return on equity of 29.22% and a negative net margin of 7,044.88%. During the same period in the prior year, the business posted $0.24 EPS. View Geron's Earnings History.

Geron is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Geron.

5 equities research analysts have issued 12-month price targets for Geron's shares. Their forecasts range from $3.00 to $4.00. On average, they anticipate Geron's stock price to reach $3.80 in the next twelve months. This suggests a possible upside of 151.7% from the stock's current price. View Analyst Price Targets for Geron.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Geron.

Media stories about GERN stock have been trending very negative recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Geron earned a daily sentiment score of -3.6 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Geron.

Some companies that are related to Geron include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), TransEnterix (TRXC), Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), Puma Biotechnology (PBYI), Dynavax Technologies (DVAX), Horizon Therapeutics (HZNP), Anavex Life Sciences (AVXL), Bristol-Myers Squibb (BMY) and Exelixis (EXEL).

Geron's stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (1.76%), SG Americas Securities LLC (0.19%), Rhumbline Advisers (0.15%), California State Teachers Retirement System (0.14%), Barclays PLC (0.07%) and Creative Planning (0.06%). Company insiders that own Geron stock include Melissa Kelly Behrs, Robert J Spiegel and Stephen Rosenfield. View Institutional Ownership Trends for Geron.

GERN stock was sold by a variety of institutional investors in the last quarter, including Metropolitan Life Insurance Co NY, State Street Corp, Commonwealth Equity Services LLC and Creative Planning. View Insider Buying and Selling for Geron.

GERN stock was acquired by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Squarepoint Ops LLC, Rhumbline Advisers, Barclays PLC, Summit X LLC and California State Teachers Retirement System. View Insider Buying and Selling for Geron.

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GERN stock can currently be purchased for approximately $1.51.

Geron has a market capitalization of $301.66 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,020,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. Geron employs 17 workers across the globe.View Additional Information About Geron.

The official website for Geron is http://www.geron.com/.

Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]